Integrating New Data From AIDS 2024: Pharmacist Perspectives

CCO Infectious Disease Podcast

Контент предоставлен Clinical Care Options, LLC and Clinical Care Options. Весь контент подкастов, включая эпизоды, графику и описания подкастов, загружается и предоставляется непосредственно компанией Clinical Care Options, LLC and Clinical Care Options или ее партнером по платформе подкастов. Если вы считаете, что кто-то использует вашу работу, защищенную авторским правом, без вашего разрешения, вы можете выполнить процедуру, описанную здесь https://ru.player.fm/legal.

5M ago 18:22

MP3•Главная эпизода

In this episode, Jennifer Cocohoba, PharmD, AAHIVP, and David Koren, PharmD, MPH, AAHIVP, FIDSA, cover the most impactful LA ART and LA PrEP clinical studies presented at AIDS 2024, including:

The PURPOSE 1 study of twice-yearly lenacapavir injections vs daily oral tenofovir as PrEP in cisgender women
An open-label extension of HPTN 084 evaluating LA CAB safety during pregnancy
48-week data from the IMPAACT 2017/MOCHA study of LA CAB + RPV in adolescents with HIV
A substudy of FLAIR evaluating the efficacy, safety, and tolerability of SC self-administration of LA CAB + RPV

Presenters:

Jennifer Cocohoba, PharmD, AAHIVP
Professor of Clinical Pharmacy
Department of Clinical Pharmacy
University of California San Francisco School of Pharmacy
San Francisco, California

David Koren, PharmD, MPH, AAHIVP, FIDSA
Adjunct Clinical Professor
Temple University School of Pharmacy
Clinical Pharmacist Specialist
Temple University Health System
Philadelphia, Pennsylvania
To access all of our new podcast episodes, subscribe to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. 

See the full program here.

424 эпизодов

#Science #Fitness #Biology #Higher Education #Podcasting Education #Medicine #Clinical Care Options, LLC #Clinical Care Options #HIV #On Covid19 #CME #Hepatitis B #Hbv #Infectious Disease Medical Education #Id Medical Education #Coronavirus #Hepatitis C #Hcv